Trial Details 50 Total Sites

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

phase

Phase 3

status

Recruiting

enrollment

4100

score

69

start date

2021-08-27

last updated

2022-01-07

Fort Worth, Texas
facility
Nebraska Cancer Specialists
1 facility
Recruiting
El Paso, Texas
facility
Texas Oncology, P.A. - El Paso; West
1 facility
Recruiting
Las Vegas, Nevada
facility
Comprehensive Cancer Centers of Nevada
1 facility
Recruiting
Bakersfield, California
facility
CBCC Global Research Inc., at Comprehensive Blood and Cancer Center
1 facility
Recruiting
Cincinnati, Ohio
facility
Oncology Hematology Care Inc
1 facility
Recruiting
Santa Rosa, California
facility
St Joseph Heritage Healthcare
1 facility
Recruiting
McKinney, Texas
facility
Texas Oncology McKinney
1 facility
Recruiting
Hollywood, Florida
facility
Memorial Healthcare System - Memorial Regional Hospital
1 facility
Recruiting
Torrance, California
facility
Torrance Memorial Physician Network/Cancer Care
1 facility
Recruiting
Van Nuys, California
facility
Valley Breast Care and Women's Health Center
1 facility
Recruiting
Stamford, Connecticut
facility
Stamford Hospital; Clincal Trials Office - 1st Fl - Bennett Cancer Cente
1 facility
Recruiting
Billings, Montana
facility
St. Vincent Frontier Cancer Center
1 facility
Recruiting